3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
34
Polycystic Ovary Syndrome
2
Infertility
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Sexual Dysfunction, Physiological
1
Prostatic Intraepithelial Neoplasia
1
Primary Dysautonomias
1
Overweight
1
Ovarian Neoplasms
1
Oligomenorrhea
1
Metabolic Syndrome
1
Kidney Diseases
1
Insulin Resistance
1
Hypertension
1
Hyperandrogenism
1
Hirsutism
1
Castration-resistant Prostate Cancer
1
Carcinoma, Ovarian Epithelial
1
Anovulation
1
Amenorrhea
1
Adenocarcinoma
1
Interventions
relacorilant
4
Hydrochlorothiazide
4
Nutrition Assessment
3
Labetalol
2
Bevacizumab
2
Angiotensin-Converting Enzyme Inhibitors
2
Amlodipine
2
ziprasidone
1
sacubitril and valsartan sodium hydrate drug combination
1
pembrolizumab
1
fimasartan
1
enzalutamide
1
clevidipine
1
cediranib
1
bicalutamide
1
aliskiren
1
Zolpidem
1
Warfarin
1
Vitamin D
1
Vecuronium Bromide
1
Vancomycin
1
Tumor Necrosis Factors
1
Tranexamic Acid
1
Tobramycin
1
Thiazides
1
Therapeutics
1
Surveys and Questionnaires
1
Sunitinib
1
Sulindac
1
Spironolactone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hypertension
×
Flutamide
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled